摘要
目的:探究依洛尤单抗对急性ST段抬高型心肌梗死(STEMI)伴2型糖尿病(T2DM)患者的影响。方法:选取2024年1—6月新余钢铁集团有限公司中心医院纳入的120例急性STEMI伴T2DM患者作为研究对象,按信封抽签法随机分为对照组(n=60)和依洛尤单抗组(n=60)。对照组采用常规治疗,依洛尤单抗组在常规治疗的基础上采用依洛尤单抗治疗,比较两组患者治疗前及治疗12个月后的胆固醇水平、炎症因子、左心室射血分数(LVEF)、N末端B型利钠肽原(NT-proBNP)、6 min步行距离及主要不良心血管事件(MACE)发生率。结果:治疗12个月后,依洛尤单抗组的残余胆固醇(RC)、TC低于对照组,HDL-C高于对照组(P<0.05);治疗12个月后,依洛尤单抗组患者的CRP、PCT、IL-6水平低于对照组(P<0.05);治疗12个月后,依洛尤单抗组的LVEF高于对照组,6 min步行距离长于对照组,NT-proBNP水平低于对照组(P<0.05);门诊或电话随访3个月,依洛尤单抗组的MACE发生率低于对照组(P<0.05)。结论:依洛尤单抗可有效调节急性STEMI伴T2DM患者的脂质代谢,减轻炎症反应,并改善心功能及运动耐量。
Objective:To investigate the effect of Evolocumab on patients with acute ST-segment elevation myocardial infarction(STEMI)and type 2 diabetes mellitus(T2DM).Method:A total of 120 patients with acute STEMI and T2DM admitted to Xinyu Iron&Steel Group Central Hospital from January to June 2024 were selected as the research subjects and randomly divided into a control group(n=60)and an Evolocumab group(n=60)using the envelope drawing method.The control group received conventional treatment,while the Evolocumab group received Evolocumab in addition to conventional treatment.The cholesterol levels,inflammatory factors,left ventricular ejection fraction(LVEF),N-terminal pro-B-type natriuretic peptide(NT-proBNP),6-minute walking distance before treatment and after 12 months of treatment,and the incidence of major adverse cardiovascular events(MACE)were compared between the two groups.Result:After 12 months of treatment,residual cholesterol(RC)and TC in the Evolocumab group were significantly lower than those in the control group,while HDL-C was significantly higher(P<0.05);after 12 months of treatment,the levels of CRP,PCT,and IL-6 in the Evolocumab group were significantly lower than those in the control group(P<0.05);after 12 months of treatment,LVEF in the Evolocumab group was significantly higher than that in the control group,the 6-minute walking distance was significantly longer than that in the control group,and the NT-proBNP level was significantly lower than that in the control group(P<0.05);after 3 months of outpatient or telephone follow-up,the incidence of MACE in the Evolocumab group was significantly lower than that in the control group(P<0.05).Conclusion:Evolocumab effectively regulates lipid metabolism,reduces inflammatory response,improves cardiac function and exercise tolerance in patients with acute STEMI and T2DM.
作者
魏谷雨
廖文军
王建中
WEI Guyu;LIAO Wenjun;WANG Jianzhong(The Laboratory Department of Xinyu Iron&Steel Group Central Hospital,Xinyu 338000,China;不详)
出处
《中国医学创新》
2025年第36期9-13,共5页
Medical Innovation of China
基金
江西省卫生健康委科技计划项目(SKJP1220244325)。
关键词
依洛尤单抗
心肌梗死
2型糖尿病
残余胆固醇
Evolocumab
Myocardial infarction
Type 2 diabetes mellitus
Residual cholesterol
